Skip to content

09 May 2022

Dr Isaac Cohen and Dr Eugen Steiner appointed to EpiEndo’s Board of Directors

EpiEndo Pharmaceuticals has appointed two new non-executive board members following the departure of Robert Helgason, who stepped down at the Company’s AGM on 26 April 2022.

Dr Isaac Cohen is currently Founder, President and CEO of Iaterion, Inc. and brings over 20 years’ experience in all phases of drug development and biopharmaceutical company management, from start-up to NASDAQ listing. He was previously Founder, Chairman and CEO of Bionovo, Inc. having also been a guest scientist at the University of California, San Francisco (UCSF) Center for Reproductive Sciences and the Comprehensive Cancer Center, and spending 20 years in private clinical practice in Berkeley, CA.


Dr. Eugen Steiner is a Venture Partner at venture capital fund HealthCap and has 35 years’ executive management experience of multistage life science companies, having raised over 100 million EUR from European and US investors. He is currently CEO of Nordic Vision Clinics AB and sits on the Boards of several public and private life science companies as well as the Stockholm School of Entrepreneurship. A former practicing physician, Dr. Steiner received his medical degree and PhD from the Karolinska Institute.

Robert Helgason is stepping down from the Board of EpiEndo to focus on his role as Founder and CEO of KOT ehf.

EpiEndo’s Board of Directors also includes Prof. Clive Page, Ívar Guðjónsson, Dr. Carl-Johan Spak, Magnús Berg Magnússon, Dr. Hilmar Bragi Janusson, and José Fernando Figueiredo as an observer.


Prof. Clive Page, Chairman of EpiEndo, said:

We’d like to thank Robert for his valuable input at EpiEndo and are pleased to welcome Isaac and Eugen to the Board. They bring broad international and industry experience from drug development to scaling up businesses, which will be invaluable as we grow.


Maria Bech, CEO of EpiEndo added:

I look forward to working with this new Board of Directors, which brings a wealth of expertise in key sector and commercial areas, to progress EpiEndo into its next phase of development”.